BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 15372209)

  • 21. Prognostic significance of volume-based 18F-FDG PET/CT parameter in patients with surgically resected non-small cell lung cancer. Comparison with immunohistochemical biomarkers.
    Lee JY; Choi JY; Heo JH; Han J; Jang SJ; Kim K; Kim J; Shim YM; Kim BT
    Nuklearmedizin; 2016; 55(1):7-14. PubMed ID: 26875430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of dual-time-point 18F-FDG PET-CT imaging in patients with head and neck squamous cell carcinoma.
    Abgral R; Le Roux PY; Rousset J; Querellou S; Valette G; Nowak E; Turzo A; Tissot V; Marianowski R; Salaün PY
    Nucl Med Commun; 2013 Jun; 34(6):551-6. PubMed ID: 23587836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High 2-[18F]fluoro-2-deoxy-d-glucose (18FDG) uptake measured by positron emission tomography is associated with reduced overall survival in patients with oral squamous cell carcinoma.
    Hofele C; Freier K; Thiele OC; Haberkorn U; Buchmann I
    Oral Oncol; 2009 Nov; 45(11):963-7. PubMed ID: 19665923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivors.
    Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Scheiderbauer J; Budach W; Kotzerke J; Bares R
    Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):54-9. PubMed ID: 16896660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential novel application of dual time point SUV measurements as a predictor of survival in head and neck cancer.
    Sanghera B; Wong WL; Lodge MA; Hain S; Stott D; Lowe J; Lemon C; Goodchild K; Saunders M
    Nucl Med Commun; 2005 Oct; 26(10):861-7. PubMed ID: 16160644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of 2-[(18) F]fluoro-2-deoxy-D-glucose positron emission tomography for patients with oral squamous cell carcinoma treated with retrograde superselective intra-arterial chemotherapy and daily concurrent radiotherapy.
    Shimizu M; Mitsudo K; Koike I; Taguri M; Iwai T; Koizumi T; Oguri S; Kioi M; Hirota M; Inoue T; Tohnai I
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Mar; 121(3):239-47. PubMed ID: 26768076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications.
    Choi JY; Jang HJ; Shim YM; Kim K; Lee KS; Lee KH; Choi Y; Choe YS; Kim BT
    J Nucl Med; 2004 Nov; 45(11):1843-50. PubMed ID: 15534053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (
    Lung MS; Hicks RJ; Pavlakis N; Link E; Jefford M; Thomson B; Wyld DK; Liauw W; Akhurst T; Kuru N; Michael M
    Asia Pac J Clin Oncol; 2020 Jun; 16(3):150-157. PubMed ID: 32030887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Differentiation of malignant and benign superficial lymph nodes by dual time point 18F-FDG PET].
    Su MG; Fan QP; Tian Y; Li FL; Yang XC; Li L; Fan CZ; Tian R
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 May; 40(3):517-20. PubMed ID: 19627018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Positron emission tomography (18)F-fluorodeoxyglucose uptake and prognosis in patients with bone and soft tissue sarcoma: A meta-analysis.
    Li YJ; Dai YL; Cheng YS; Zhang WB; Tu CQ
    Eur J Surg Oncol; 2016 Aug; 42(8):1103-14. PubMed ID: 27189833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical utility of 2-[(18)F] fluoro-2-deoxy-D-glucose positron emission tomography in predicting World Health Organization grade in pancreatic neuroendocrine tumors.
    Tomimaru Y; Eguchi H; Tatsumi M; Kim T; Hama N; Wada H; Kawamoto K; Kobayashi S; Morii E; Mori M; Doki Y; Nagano H
    Surgery; 2015 Feb; 157(2):269-76. PubMed ID: 25311263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer.
    Imdahl A; Nitzsche E; Krautmann F; Högerle S; Boos S; Einert A; Sontheimer J; Farthmann EH
    Br J Surg; 1999 Feb; 86(2):194-9. PubMed ID: 10100786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
    Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
    Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluorodeoxyglucose positron emission tomography and the prognosis of pancreatic carcinoma.
    Zimny M; Fass J; Bares R; Cremerius U; Sabri O; Buechin P; Schumpelick V; Buell U
    Scand J Gastroenterol; 2000 Aug; 35(8):883-8. PubMed ID: 10994629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer.
    Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Budach W; Langen HJ; Bares R
    Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):463-71. PubMed ID: 17103167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of FDG uptake in early stage non-small cell lung cancer.
    Hanin FX; Lonneux M; Cornet J; Noirhomme P; Coulon C; Distexhe J; Poncelet AJ
    Eur J Cardiothorac Surg; 2008 May; 33(5):819-23. PubMed ID: 18374589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer.
    Hellwig D; Gröschel A; Graeter TP; Hellwig AP; Nestle U; Schäfers HJ; Sybrecht GW; Kirsch CM
    Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):13-21. PubMed ID: 16151765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value.
    Van Laere K; Ceyssens S; Van Calenbergh F; de Groot T; Menten J; Flamen P; Bormans G; Mortelmans L
    Eur J Nucl Med Mol Imaging; 2005 Jan; 32(1):39-51. PubMed ID: 15309329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regional nodal staging with 18F-FDG PET-CT in non-small cell lung cancer: Additional diagnostic value of CT attenuation and dual-time-point imaging.
    Li M; Wu N; Liu Y; Zheng R; Liang Y; Zhang W; Zhao P
    Eur J Radiol; 2012 Aug; 81(8):1886-90. PubMed ID: 21511421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.